ARTICLE | Company News
Breakthrough designation for Roche's alectinib
September 24, 2013 12:53 AM UTC
Roche (SIX:ROG; OTCQX:RHHBY) said FDA granted breakthrough therapy designation for alectinib (RO5424802/ CH5424802) to treat anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC...